On Tuesday, Kymera Therapeutics Inc (NASDAQ: KYMR) opened lower -5.58% from the last session, before settling in for the closing price of $33.70. Price fluctuations for KYMR have ranged from $29.07 to $53.27 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 233.20% annually for the last half of the decade. Company’s average yearly earnings per share was noted -21.97% at the time writing. With a float of $53.96 million, this company’s outstanding shares have now reached $64.89 million.
In an organization with 188 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 88.53%, operating margin of -545.36%, and the pretax margin is -475.57%.
Kymera Therapeutics Inc (KYMR) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Kymera Therapeutics Inc is 16.91%, while institutional ownership is 95.07%. The most recent insider transaction that took place on Mar 03 ’25, was worth 68,239. In this transaction Chief Legal Officer of this company sold 2,241 shares at a rate of $30.45, taking the stock ownership to the 80,085 shares. Before that another transaction happened on Mar 03 ’25, when Company’s Chief Operating Officer sold 1,383 for $30.45, making the entire transaction worth $42,113. This insider now owns 67,800 shares in total.
Kymera Therapeutics Inc (KYMR) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.91 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -21.97% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -10.17% during the next five years compared to -26.36% drop over the previous five years of trading.
Kymera Therapeutics Inc (NASDAQ: KYMR) Trading Performance Indicators
Check out the current performance indicators for Kymera Therapeutics Inc (KYMR). In the past quarter, the stock posted a quick ratio of 7.53. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 43.90.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.97, a number that is poised to hit -0.90 in the next quarter and is forecasted to reach -4.11 in one year’s time.
Technical Analysis of Kymera Therapeutics Inc (KYMR)
Let’s dig in a bit further. During the last 5-days, its volume was 0.58 million. That was inferior than the volume of 0.59 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 26.61%. Additionally, its Average True Range was 2.08.
During the past 100 days, Kymera Therapeutics Inc’s (KYMR) raw stochastic average was set at 11.38%, which indicates a significant decrease from 27.93% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.11% in the past 14 days, which was lower than the 59.49% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $36.55, while its 200-day Moving Average is $41.51. However, in the short run, Kymera Therapeutics Inc’s stock first resistance to watch stands at $33.44. Second resistance stands at $35.06. The third major resistance level sits at $36.01. If the price goes on to break the first support level at $30.86, it is likely to go to the next support level at $29.91. The third support level lies at $28.29 if the price breaches the second support level.
Kymera Therapeutics Inc (NASDAQ: KYMR) Key Stats
There are currently 64,944K shares outstanding in the company with a market cap of 2.07 billion. Presently, the company’s annual sales total 47,070 K according to its annual income of -223,860 K. Last quarter, the company’s sales amounted to 7,390 K and its income totaled -70,750 K.
